3.07
3.07 (0.74%)
As of Mar 06, 2024
Trevi Therapeutics, Inc. [TRVI]
Source:
Company Overview
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) to treat serious neurologically mediated conditions. We are developing Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, or IPF.
Country | United States |
Headquarters | new haven, connecticut |
Phone Number | 203-304-2499 |
Industry | manufacturing |
CEO | Jennifer Good |
Website | www.trevitherapeutics.com |